<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Inpatient Antibiotic Guide</title>
<style>
  body { font-family: Arial; margin: 0; display: flex; height: 100vh; }
  #sidebar { width: 250px; background: #2c3e50; color: white; padding: 20px; overflow-y: auto; }
  #sidebar h2 { margin-top: 0; }
  #sidebar ul { list-style: none; padding-left: 0; }
  #sidebar li { padding: 10px; cursor: pointer; border-radius: 5px; }
  #sidebar li:hover { background-color: #34495e; }
  #content { flex-grow: 1; padding: 20px; overflow-y: auto; }
  h1, h2, h3 { margin-top: 0.5em; }
  table { border-collapse: collapse; width: 100%; margin-bottom: 20px; }
  th, td { border: 1px solid #bdc3c7; padding: 8px; text-align: left; }
  th { background-color: #ecf0f1; }
  .expandable { cursor: pointer; color: #2980b9; margin: 10px 0; }
  .hidden { display: none; }
  .firstline { background-color: #dff0d8; }
  .alternative { background-color: #fcf8e3; }
  .caution { background-color: #f2dede; }
</style>
</head>
<body>

<div id="sidebar">
  <h2>Sections</h2>
  <ul>
    <li onclick="showContent('cap')">Community-Acquired Pneumonia</li>
    <li onclick="showContent('hap')">Hospital-Acquired Pneumonia</li>
    <li onclick="showContent('uti')">Urinary Tract Infection</li>
    <li onclick="showContent('ssi')">Skin & Soft Tissue Infection</li>
    <li onclick="showContent('iab')">Intra-Abdominal Infection</li>
    <li onclick="showContent('cns')">CNS Infection</li>
    <li onclick="showContent('endocarditis')">Endocarditis</li>
    <li onclick="showContent('pathogen')">Pathogen-Based Guidance</li>
  </ul>
</div>

<div id="content">
  <div style="text-align:center; margin-top:50px;">
    <img src="mutant-icon.png" alt="Mutant Icon" style="width:150px; height:150px; margin-bottom:20px;">
    <h1>Welcome to the Inpatient Antibiotic Guide</h1>
    <p>Select a section from the sidebar to view empiric therapy, Gram-stain guidance, culture-directed therapy, or pathogen-based escalation guidance.</p>
  </div>
</div>


<script>
const contentData = {
  cap: `
    <h2>Community-Acquired Pneumonia (CAP)</h2>
    <h3>Empiric Therapy</h3>
    <table>
      <tr><th>Drug</th><th>Dose</th><th>Notes</th><th>References</th></tr>
      <tr class="firstline"><td>Amoxicillin</td><td>1 g PO TID</td><td>First-line for non-severe CAP</td><td>IDSA 2019, NEJM 2021</td></tr>
      <tr class="alternative"><td>Doxycycline</td><td>100 mg PO BID</td><td>Allergy alternative</td><td>IDSA 2019</td></tr>
    </table>
    <div class="expandable" onclick="toggleVisibility('capGram')">Gram-Stain Guidance</div>
    <div id="capGram" class="hidden">
      <ul>
        <li>Gram-positive cocci → Cover S. pneumoniae</li>
        <li>Gram-negative rods → Broaden coverage (Pseudomonas, Enterobacteriaceae)</li>
        <li>Clusters → Add MRSA coverage if risk factors present</li>
      </ul>
    </div>
    <div class="expandable" onclick="toggleVisibility('capCulture')">Culture-Directed Therapy</div>
    <div id="capCulture" class="hidden">
      <table>
        <tr><th>Pathogen</th><th>Drug</th><th>Dose</th><th>Duration</th><th>References</th></tr>
        <tr><td>Streptococcus pneumoniae</td><td>Penicillin / Ceftriaxone</td><td>Pen G 2M units IV q4h / Ceftriaxone 1g IV daily</td><td>5–7d</td><td>IDSA 2019</td></tr>
        <tr><td>MRSA</td><td>Vancomycin / Linezolid</td><td>Vanc 15 mg/kg IV q12h / Linezolid 600 mg IV/PO q12h</td><td>7–14d</td><td>IDSA 2019</td></tr>
      </table>
    </div>
  `,

  hap: `
    <h2>Hospital-Acquired Pneumonia (HAP)</h2>
    <h3>Empiric Therapy</h3>
    <table>
      <tr><th>Drug</th><th>Dose</th><th>Notes</th><th>References</th></tr>
      <tr class="firstline"><td>Vancomycin</td><td>15 mg/kg IV q12h</td><td>MRSA coverage</td><td>IDSA 2016</td></tr>
      <tr class="firstline"><td>Piperacillin-Tazobactam</td><td>4.5 g IV q6h</td><td>Gram-negative coverage incl. Pseudomonas</td><td>IDSA 2016</td></tr>
    </table>
    <div class="expandable" onclick="toggleVisibility('hapGram')">Gram-Stain Guidance</div>
    <div id="hapGram" class="hidden">
      <ul>
        <li>Gram-positive cocci → MRSA coverage</li>
        <li>Gram-negative rods → Continue broad-spectrum beta-lactam</li>
      </ul>
    </div>
    <div class="expandable" onclick="toggleVisibility('hapCulture')">Culture-Directed Therapy</div>
    <div id="hapCulture" class="hidden">
      <table>
        <tr><th>Pathogen</th><th>Drug</th><th>Dose</th><th>Duration</th><th>References</th></tr>
        <tr><td>MRSA</td><td>Vancomycin / Linezolid</td><td>Vanc 15 mg/kg IV q12h / Linezolid 600 mg IV/PO q12h</td><td>7–14d</td><td>IDSA 2016</td></tr>
        <tr><td>Pseudomonas</td><td>Cefepime / Piperacillin-Tazobactam / Meropenem</td><td>Standard IV dosing per IDSA</td><td>7–10d</td><td>IDSA 2016</td></tr>
      </table>
    </div>
  `,

  uti: `
    <h2>Urinary Tract Infection (UTI)</h2>
    <h3>Empiric Therapy</h3>
    <table>
      <tr><th>Drug</th><th>Dose</th><th>Notes</th><th>References</th></tr>
      <tr class="firstline"><td>Ceftriaxone</td><td>1 g IV daily</td><td>Uncomplicated inpatient UTI</td><td>IDSA 2019</td></tr>
      <tr class="alternative"><td>Ciprofloxacin</td><td>400 mg IV q12h</td><td>Alternative for allergy/resistant pathogen</td><td>IDSA 2019</td></tr>
    </table>
    <div class="expandable" onclick="toggleVisibility('utiGram')">Gram-Stain Guidance</div>
    <div id="utiGram" class="hidden">
      <ul>
        <li>Gram-negative rods → Continue broad-spectrum coverage (E. coli, Klebsiella)</li>
        <li>Gram-positive cocci → Consider Enterococcus coverage</li>
      </ul>
    </div>
  `,

  ssi: `
    <h2>Skin & Soft Tissue Infection (SSI)</h2>
    <h3>Empiric Therapy</h3>
    <table>
      <tr><th>Drug</th><th>Dose</th><th>Notes</th><th>References</th></tr>
      <tr class="firstline"><td>Cephalexin</td><td>500 mg PO QID</td><td>Mild infection</td><td>IDSA 2014</td></tr>
      <tr class="alternative"><td>Clindamycin</td><td>300 mg PO TID</td><td>Allergy alternative</td><td>IDSA 2014</td></tr>
      <tr class="caution"><td>Vancomycin</td><td>15 mg/kg IV q12h</td><td>Severe or MRSA risk</td><td>IDSA 2014</td></tr>
    </table>
  `,

  iab: `<h2>Intra-Abdominal Infection (IAI)</h2><p>Empiric therapy depends on severity and source; often broad-spectrum beta-lactams ± metronidazole. Adjust per culture.</p>`,

  cns: `<h2>CNS Infection</h2><p>Empiric therapy guided by age, immune status, and risk factors: Vancomycin + Ceftriaxone ± Ampicillin. Adjust per Gram stain and culture.</p>`,

  endocarditis: `<h2>Endocarditis</h2><p>Empiric therapy: Vancomycin ± Gentamicin until blood cultures return. Adjust therapy per pathogen and susceptibility.</p>`,

  pathogen: `
<h2>Pathogen-Based Guidance</h2>

<div class="expandable" onclick="toggleVisibility('gpClusters')">Gram-positive cocci (clusters, MRSA)</div>
<div id="gpClusters" class="hidden">
  <table>
    <tr>
      <th>Organism</th>
      <th>Empiric Coverage</th>
      <th>Typical Dosing</th>
      <th>Alternative / Escalation</th>
      <th>Notes</th>
      <th>References</th>
    </tr>
    <tr class="firstline">
      <td>Staphylococcus aureus (MRSA)</td>
      <td>Vancomycin IV</td>
      <td>15 mg/kg IV q12h</td>
      <td>Linezolid IV/PO 600 mg q12h</td>
      <td>Adjust for renal function; monitor troughs</td>
      <td>IDSA 2016</td>
    </tr>
    <tr class="alternative">
      <td>Staphylococcus aureus (MSSA)</td>
      <td>Nafcillin / Oxacillin IV</td>
      <td>2 g IV q4h</td>
      <td>Cefazolin IV 2 g q8h</td>
      <td>First-line if MSSA confirmed</td>
      <td>IDSA 2016</td>
    </tr>
  </table>
</div>

<div class="expandable" onclick="toggleVisibility('gpChains')">Gram-positive cocci (chains, Enterococcus)</div>
<div id="gpChains" class="hidden">
  <table>
    <tr>
      <th>Organism</th>
      <th>Empiric Coverage</th>
      <th>Typical Dosing</th>
      <th>Alternative / Escalation</th>
      <th>Notes</th>
      <th>References</th>
    </tr>
    <tr class="firstline">
      <td>Enterococcus faecalis</td>
      <td>Ampicillin IV</td>
      <td>2 g IV q4h</td>
      <td>Vancomycin IV 15 mg/kg q12h if resistant</td>
      <td>Adjust dosing for renal function</td>
      <td>IDSA 2016</td>
    </tr>
    <tr class="alternative">
      <td>Enterococcus faecium (VRE)</td>
      <td>Linezolid IV/PO 600 mg q12h</td>
      <td>-</td>
      <td>Daptomycin IV 6–8 mg/kg q24h</td>
      <td>Consider ICU setting and severity</td>
      <td>IDSA 2016</td>
    </tr>
  </table>
</div>

<div class="expandable" onclick="toggleVisibility('gnRods')">Gram-negative rods (Enterobacteriaceae, Pseudomonas)</div>
<div id="gnRods" class="hidden">
  <table>
    <tr>
      <th>Organism</th>
      <th>Empiric Coverage</th>
      <th>Typical Dosing</th>
      <th>Alternative / Escalation</th>
      <th>Notes</th>
      <th>References</th>
    </tr>
    <tr class="firstline">
      <td>Escherichia coli</td>
      <td>Cefepime IV</td>
      <td>2 g IV q8h</td>
      <td>Piperacillin-Tazobactam IV 4.5 g q6h</td>
      <td>Check local antibiogram; adjust renal</td>
      <td>IDSA 2016</td>
    </tr>
    <tr class="firstline">
      <td>Klebsiella pneumoniae</td>
      <td>Cefepime IV</td>
      <td>2 g IV q8h</td>
      <td>Meropenem IV 1 g q8h if resistant</td>
      <td>Consider ESBL risk</td>
      <td>IDSA 2016</td>
    </tr>
    <tr class="alternative">
      <td>Pseudomonas aeruginosa</td>
      <td>Cefepime IV</td>
      <td>2 g IV q8h</td>
      <td>Meropenem IV 1 g q8h if resistant</td>
      <td>Combination therapy if critically ill</td>
      <td>IDSA 2016</td>
    </tr>
  </table>
</div>

<div class="expandable" onclick="toggleVisibility('anaerobes')">Anaerobes (Bacteroides, Clostridium)</div>
<div id="anaerobes" class="hidden">
  <table>
    <tr>
      <th>Organism</th>
      <th>Empiric Coverage</th>
      <th>Typical Dosing</th>
      <th>Alternative / Escalation</th>
      <th>Notes</th>
      <th>References</th>
    </tr>
    <tr class="firstline">
      <td>Bacteroides fragilis</td>
      <td>Metronidazole IV/PO</td>
      <td>500 mg IV q8h or 500 mg PO q8h</td>
      <td>Piperacillin-Tazobactam IV 4.5 g q6h</td>
      <td>Often combined with Gram-negative coverage</td>
      <td>IDSA 2016</td>
    </tr>
    <tr class="firstline">
      <td>Clostridium perfringens</td>
      <td>Penicillin IV</td>
      <td>3–4 M units IV q4–6h</td>
      <td>Consider adding Clindamycin IV 900 mg q8h for toxin suppression</td>
      <td>Severe soft tissue infections</td>
      <td>IDSA 2014</td>
    </tr>
  </table>
</div>

<div class="expandable" onclick="toggleVisibility('intracellular')">Intracellular bacteria (Legionella, Mycoplasma, Chlamydia)</div>
<div id="intracellular" class="hidden">
  <table>
    <tr>
      <th>Organism</th>
      <th>Empiric Coverage</th>
      <th>Typical Dosing</th>
      <th>Alternative / Escalation</th>
      <th>Notes</th>
      <th>References</th>
    </tr>
    <tr class="firstline">
      <td>Legionella pneumophila</td>
      <td>Azithromycin IV/PO</td>
      <td>500 mg IV/PO day 1, then 250 mg daily x4d</td>
      <td>Doxycycline IV/PO 100 mg q12h</td>
      <td>Duration: 7–14 days depending on severity</td>
      <td>IDSA 2019</td>
    </tr>
    <tr class="firstline">
      <td>Mycoplasma pneumoniae</td>
      <td>Doxycycline IV/PO</td>
      <td>100 mg IV/PO q12h</td>
      <td>Azithromycin IV/PO as alternative</td>
      <td>Usually 5–7 days</td>
      <td>IDSA 2019</td>
    </tr>
    <tr class="firstline">
      <td>Chlamydia pneumoniae</td>
      <td>Doxycycline IV/PO</td>
      <td>100 mg IV/PO q12h</td>
      <td>Azithromycin IV/PO as alternative</td>
      <td>Usually 7–10 days</td>
      <td>IDSA 2019</td>
    </tr>
  </table>
</div>


  `
};

function showContent(section) {
  document.getElementById('content').innerHTML = contentData[section];
}

function toggleVisibility(id) {
  const elem = document.getElementById(id);
  elem.classList.toggle('hidden');
}
</script>

</body>
</html>
